Johnson & Johnson
2Q Revenues: $20.8 billion (+11%)
2Q Earnings: $4.0 billion (+3%)
YTD Revenues: $40.8 billion (+12%)
YTD Earnings: $8.3 billion (+1%)
Comments: Worldwide Pharmaceutical sales were $10.4 billion in the quarter, up 20%. Domestic sales increased 18% and international sales increased 23%. Sales included the impact of Actelion Ltd. which contributed 6.6%, to worldwide operational sales growth. Growth was driven by Stelara, up 36% to $1.3 billion; Zytiga up 63% to $909 million; Darzalex, up 71% to $511 million; Imbruvica, up 38% to $620 million; Simponi/Simponi Aria, up 25% to $548 million; Invega Sustenna, up 15% to $720 million; and Xarelto up 6% to $679 million. Remicade sales were down 14% to $1.3 billion in the quarter.